Ticagrelor (brilinta), an antiplatelet drug for acute coronary syndrome.
نویسندگان
چکیده
Ticagrelor (Brilinta) for acute coronary syndrome.
منابع مشابه
Ticagrelor (Brilinta) for secondary prevention of thrombotic events following acute coronary syndrome.
Volume 88, Number 12 www.aafp.org/afp American Family Physician 821 Ticagrelor (Brilinta) is a newer, reversible P2Y12 platelet inhibitor. Older, irreversible P2Y12 receptor inhibitors include prasugrel (Effient), clopidogrel (Plavix), and ticlopidine. Ticagrelor is labeled for the prevention of vascular events and death in patients with acute coronary syndrome.1 STEPS new drug reviews cover Sa...
متن کاملTicagrelor: a novel reversible oral antiplatelet agent.
The complex mechanism of platelet activation creates an optimal target for pharmacological treatment in patients with acute coronary syndromes. Current antiplatelet medications that are used in addition to aspirin include the thienopyridines, clopidogrel and prasugrel, but there are several limitations to the use of these medications. Clopidogrel and prasugrel irreversibly bind to the P2Y12 rec...
متن کاملAdvances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
Antiplatelet therapy is widely used with proven benefit for the prevention of further ischemic cardiac complications in patients with acute coronary syndrome. Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including ticagrelor, prasugrel, or clopidogrel in combination with aspirin to comprise dual antipla...
متن کاملA Rare Case of Ticagrelor-Induced Profound Isolated Thrombocytopenia.
Ticagrelor is a new oral antiplatelet drug that has a strong proven benefit of reducing the rate of death from cardiovascular causes, myocardial infarction, and stroke compared with clopidogrel. Ticagrelor is widely used by patients with acute coronary syndrome. However, profound thrombocytopenia has never been previously reported in such patients. We herein present our experience with a case o...
متن کاملTicagrelor – toward more efficient platelet inhibition and beyond
Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor, is unique among antiplatelet drugs, because ticagrelor inhibits the platelet P2Y12 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- P & T : a peer-reviewed journal for formulary management
دوره 37 10 شماره
صفحات -
تاریخ انتشار 2012